Best Practices in Hematologic Malignancies – December 2017 Vol 8

Letters from Lillie

Navigation on the March—Next Stop, Hematology

Lillie D. Shockney, RN, BS, MAS, ONN-CG 

Dear Navigators, Oncology navigation has made great strides in improving cancer care, including access to quality care, for nearly 3 decades. Navigation programs are well established for most patient populations [ Read More ]

Myeloproliferative Neoplasms

Symptom Burden Linked to Disability Leave Among Patients with Myeloproliferative Neoplasms


A recent survey of patients with myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia, has identified a strong association between symptom burden and medical disability leave. According to [ Read More ]

Multiple Myeloma

Treating Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients


Recent advances in the treatment of multiple myeloma have dramatically altered the trajectory of disease, as providers now have several efficacious agents in various drug classes at their disposal. At [ Read More ]

Multiple Myeloma

Treatment of Relapsed/Refractory Multiple Myeloma

Despite major and continuing treatment interventions, myeloma remains incurable for most patients, and relapse is an expected part of the disease course. At the National Comprehensive Cancer Network 12th Annual [ Read More ]

Multiple Myeloma

Darzalex Combined with Pomalidomide and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma

Daratumumab (Darzalex), in combination with pomalidomide (Pomalyst) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies, including lenalidomide (Revlimid) and a [ Read More ]

Leukemia and Lymphoma, Survivorship

Lymphoma Survivorship Care: Getting Back to Life After Treatment

With 5-year survival rates for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) at 86% and 71%, respectively, the number of lymphoma survivors is on the rise, but achieving long-term quality [ Read More ]

Leukemia and Lymphoma

New Therapeutic Agents for the Treatment of B-Cell Acute Lymphocytic Leukemia

Treatments targeting immune responses against solid tumors have led to dramatic improvements in patient outcomes, but the role for immunotherapy in the treatment of acute leukemia is still being defined. [ Read More ]

Leukemia and Lymphoma

Targeted Therapy for Acute Myeloid Leukemia

After nearly 40 years of negligible drug development, 2017 saw the approval of 4 drugs by the FDA for the treatment of acute myeloid leukemia (AML). These novel regimens have [ Read More ]

Leukemia and Lymphoma

Enasidenib, a New Targeted Therapy Approved for Relapsed or Refractory AML, Shows Complete Remission in Some Patients

On August 1, 2017, the FDA approved enasidenib (Idhifa), an isocitrate dehydrogenase-2 inhibitor, for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have the IDH2 [ Read More ]

Leukemia and Lymphoma

Vyxeos First Treatment Approved Specifically for 2 Types of High-Risk AML

The FDA, on August 3, 2017, approved a fixed combination daunorubicin plus cytarabine (Vyxeos) injection for the treatment of adults with 2 types of acute myeloid leukemia (AML)—newly diagnosed, therapy-related [ Read More ]

Leukemia and Lymphoma

Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

On August 17, 2017, the FDA approved inotuzumab ozogamicin (Besponsa), a targeted therapy, for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks [ Read More ]

Leukemia and Lymphoma

Kymriah First Gene Therapy Approved by the FDA; Indicated for Young Patients with B-Cell ALL and CD19

Tisagenlecleucel (Kymriah), a genetically modified chimeric antigen receptor (CAR) T-cell immunotherapy, was approved by the FDA on August 30, 2017, for the treatment of pediatric patients and young adults aged [ Read More ]

Leukemia and Lymphoma

Mylotarg Now Approved for the Treatment of Patients with CD33-Positive AML

On September 1, 2017, the FDA approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), as well as patients aged ≥2 years [ Read More ]

FDA Updates

Recent FDA Approvals

Calquence Approved for Mantle Cell Lymphoma Yescarta CAR T-Cell Therapy Approved for Large B-Cell Lymphoma Aliqopa Approved for Adults with Relapsed Follicular Lymphoma Actemra First FDA-Approved Treatment for CAR T-Cell–Induced [ Read More ]